Semuloparin Sodium

Summary

Semuloparin Sodium (CHEMBL2108718) is a phase-3 clinical-stage oligosaccharide; indicated across 2 conditions including venous thromboembolism.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• Indications: 2 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108718
Name	Semuloparin Sodium
Type	Oligosaccharide
Max phase	3

Also known as: AVE-5026, Mulsevo, Semuloparin sodium, Semuloparina sodica, Semuloparine sodique, Visamerin, SEMULOPARIN SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
venous thromboembolism	3	MONDO:0005399	EFO:0004286

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00679588	PHASE3	COMPLETED	Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
NCT00694382	PHASE3	COMPLETED	Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
NCT00697099	PHASE3	COMPLETED	Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
NCT00709904	PHASE3	COMPLETED	Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
NCT00714597	PHASE3	TERMINATED	Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
NCT00718224	PHASE3	COMPLETED	Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
NCT00721760	PHASE3	COMPLETED	Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
NCT00331838	PHASE2	COMPLETED	Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
NCT01567904	PHASE2	TERMINATED	Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).